NCT07509385Not yet recruiting
The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt
Source: ClinicalTrials.gov · Last updated 3 Apr 2026
Brief summary (registry, in English)
Study aimsTo measure the serum levels of IL-17 A and IL-10 in newly diagnosed patients with B-cell acute lymphoblastic leukemia (B-ALL). 2-To study the association between serum cytokine levels (IL-17 A and IL-10) and laboratory parameters, as well as the response to treatment
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 29 Mar 2026
- Start date
- 31 Mar 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07509385
What you commit to
- Study type: Observational
- Planned participants: 80
- From 31 Mar 2026 to the primary completion date, 30 Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients who received chemotherapy or immunotherapy
Other illness
- patients with other malignancies
Who the study is looking for
- Newly diagnosed acute B lymphoblastic leukemia patient
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.